scholarly journals Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer

2019 ◽  
Author(s):  
Alpaslan Kaban ◽  
Samet Topuz ◽  
Hamdullah Sözen ◽  
Yavuz Salihoğlu
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Survival Rates ◽  
Term Survival ◽  
Long Term Survival ◽  
Primary Surgery

scholarly journals Comparison of Long-Term Survival Rates of Primary Surgery and Surgery After Neoadjuvant Chemotherapy in Ovarian Cancer

2019 ◽  
Vol 20 (2) ◽  
pp. 88-93
Author(s):  
Alpaslan Kaban ◽  
Samet Topuz ◽  
Hamdullah Sözen ◽  
Yavuz Salihoğlu
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Survival Rates ◽  
Term Survival ◽  
Long Term Survival ◽  
Primary Surgery

Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study

2014 ◽  
Vol 132 (2) ◽  
pp. 292-298 ◽  
Author(s):  
Carsten Lindberg Fagö-Olsen ◽  
Bent Ottesen ◽  
Henrik Kehlet ◽  
Sofie L. Antonsen ◽  
Ib J. Christensen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Term Survival ◽  
Long Term Survival ◽  
Danish Study

Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis

2020 ◽  
pp. ijgc-2020-001392 ◽  
Author(s):  
Chen Nahshon ◽  
Ofra Barnett-Griness ◽  
Yakir Segev ◽  
Meirav Schmidt ◽  
Ludmila Ostrovsky ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Conditional Probability ◽  
Systematic Reviews ◽  
Survival Rates ◽  
Systemic Review ◽  
Brca Mutations ◽  
Term Survival ◽  
Long Term Survival ◽  
Over Time

IntroductionShort-term survival rates of patients with BRCA-mutated ovarian cancer have been previously shown to be longer than those of non-carriers. We aimed to study the long-term survival rates of these patients and investigate whether the 5-year advantage decreases over time.MethodsA systematic review of the literature was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyzes (PRISMA) statement. The study protocol can be assessed at PROSPERO International prospective register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO, registration number CRD42019137455). We considered for inclusion studies providing Kaplan–Meier survival curves up to and including 10 years, comparing patients with ovarian cancer with and without BRCA mutations. Our main outcome was the conditional probability of surviving an additional 5 years.ResultsA total of 13 references comprising 4565 patients was analyzed, of which 1131 BRCA1/2-mutated carriers and 3434 non-carriers were included. The expected higher 5-year survival rate in BRCA-mutated patients was observed (risk difference (RD)=14.9%, p=0.0002, risk ratio (RR)=1.36, p=0.001). Ten-year survival rates were comparatively less improved in BRCA-mutated patients (RD=8.6%, p=0.042, RR=1.25, p=0.12). After already surviving 5 years, no advantage in probability of further surviving 5 additional years was observed for the BRCA-mutated group (RD=2.9%, p=0.71, RR=0.97, p=0.78).ConclusionOur results provide insight into long-term survival rates and prognosis in patients with BRCA-mutated ovarian cancer which suggest that, despite the improved 5-year prognosis, the conditional probability of surviving an additional 5 years does not show the same advantage. The relatively low long-term advantage highlights the significance of epithelial ovarian cancer recurrence prevention. In the era of poly adenosine ribose inhibitors, future studies should explore the adequate follow-up and the benefit of a longer maintenance treatment phase, aiming to prolong the long-term survival of BRCA-mutated patients.

Neoadjuvant Chemotherapy for Advanced Ovarian Cancer: Long-Term Survival

1999 ◽  
Vol 72 (1) ◽  
pp. 93-99 ◽  
Author(s):  
Peter E. Schwartz ◽  
Thomas J. Rutherford ◽  
Joseph T. Chambers ◽  
Ernest I. Kohorn ◽  
Robert P. Thiel
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
Term Survival ◽  
Long Term Survival

Lessons from ovarian cancer patients with more than 10 years survival

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15059-15059
Author(s):  
K. Kudoh ◽  
M. Takano ◽  
T. Kita ◽  
T. Yoshikawa ◽  
K. Furuya ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Size ◽  
Survival Rates ◽  
Residual Tumor ◽  
Stage Iiic ◽  
Term Survival ◽  
Long Term Survival ◽  
Initial Surgery ◽  
Stage Ia

15059 Background: Purpose of this retrospective study is to explore predictive factors for long-term survival in patients with primary epithelial ovarian carcinoma. Methods: Total 161 patients treated from March 1983 to December 1994 at the National Defense medical College hospital were enrolled in this study. Profiles and characteristics of patients with long-term survival were retrospectively examined. Results: All patients with stage IA-B or IIA-B survived more than 10 years although 2 of patients with stage IA and IB tumor were dead of primary disease and one patient was dead of other disease after more than 10 years follow-up. More than half of patients with stage IC, IIC or IIIA-B survived more than 10 years, while 10-years’ survival rates of patients with stage IIIC or IV were only 10% with marked increase of death by primary disease. All patients with stage I or IIA-B without residual tumor after initial surgery survived more than 10 years. Although long-term survival rates of patients with stage IIC or IIIA-B were higher in patients without residual tumor after initial surgery, 6 out of 7 patients with stage IIIC or IV had residual tumor. Analysis of 70 patients with stage III or IV ovarian cancer revealed that residual tumor size, histologic types and response to initial chemotherapy affected significantly long-term survival. Conclusions: We demonstrated that predictors for long-term survival were stage, residual tumor size after initial surgery, histology and response to initial chemotherapy. [Table: see text] No significant financial relationships to disclose.

scholarly journals Long-term survival with multiple metastasectomies for pulmonary osteosarcoma: a case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Satoshi Takamori ◽  
Hiroyuki Oizumi ◽  
Jun Suzuki ◽  
Katsuyuki Suzuki
Keyword(s):  
Case Report ◽  
Pulmonary Metastases ◽  
Multidisciplinary Treatment ◽  
Underlying Disease ◽  
Pulmonary Metastasectomy ◽  
Extensive Resection ◽  
Term Survival ◽  
Long Term Survival ◽  
Primary Surgery

Abstract Background Repeat pulmonary metastasectomy (PM) considerably improves the prognosis of patients with pulmonary metastases of osteosarcoma. Reports have demonstrated a significantly improved prognosis in patients who have undergone repeat metastasectomy for osteosarcoma; however, there have been no reports with more than six metastasectomies. Herein, we describe the long-term survival of a patient following resection of multiple tumors and other treatments for metastatic osteosarcoma. Case presentation A 28-year-old woman underwent extensive resection and postoperative adjuvant chemotherapy for right tibial sarcoma. Over the years, she developed repeated pulmonary metastases. First, 116 metastases were removed from the bilateral lungs. After that, multiple PMs of approximately 250 tumors and other treatments for deep metastatic lesions were performed. The patient died of the underlying disease 24 years after the primary surgery. Conclusions This case report demonstrates the long-term survival benefit of a multidisciplinary treatment centered on multiple metastasectomies.

Sign in / Sign up

Export Citation Format

Share Document